Dr Reddy’s launch Lansoprazole DR orally disintegrating tablets in US
They are indicated for the treatment of duodenal ulcers, gastric ulcers, GERD, erosive esophagitis and Zollinger-Ellison syndrome
Dr Reddy’s Laboratories announced the launch of Lansoprazole DR orally disintegrating tablets, a therapeutic equivalent generic version of Prevacid SoluTab Delayed-Release Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the US Food and Drug Administration (USFDA).
Prevacid is a trademark of Takeda Pharmaceuticals USA.
They are indicated for the treatment of duodenal ulcers, gastric ulcers, GERD, erosive esophagitis and pathological hypersecretory syndromes.
The Prevacid brand and generic had US sales of approximately $87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.
Dr Reddy’s Lansoprazole DR Orally Disintegrating Tablets are available in 15 mg and 30 mg tablets in unit-dose packages of 100 (10 x 10).